# Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab

> **NCT01748292** · PHASE3 · COMPLETED · sponsor: **Charles C Wykoff, PhD, MD** · enrollment: 60 (actual)

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** 0.5 mg ranibizumab

## Key facts

- **NCT ID:** NCT01748292
- **Lead sponsor:** Charles C Wykoff, PhD, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2017-02
- **Final completion:** 2017-02
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2019-06-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01748292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01748292, "Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01748292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*